Search

Displaying results 921 - 930 of 2872 in total
  1. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  2. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA ...

  4. Drug

    Mavoglurant

    go.drugbank.com/drugs/DB13004
    Investigational

    Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).

  5. Drug

    Doconexent

    go.drugbank.com/drugs/DB03756
    ApprovedInvestigational

    A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic aci...

    Mixtures: P-NATAL®, Virt-Pn DHACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors
  6. Drug

    PF-06815345

    go.drugbank.com/drugs/DB14862
    Investigational

    PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).

  7. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However...

  8. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Balsam of Peru

    go.drugbank.com/drugs/DB11482
    ApprovedNutraceuticalVet approved

    [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products.

  10. Drug

    Clindamycin

    go.drugbank.com/drugs/DB01190
    ApprovedInvestigationalVet approved

    [A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Clindacin P